Temporal trends of epilepsy in multiple sclerosis
Open Access
- 18 July 2022
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 146 (5), 492-498
- https://doi.org/10.1111/ane.13671
Abstract
Objectives Epilepsy is associated with advanced multiple sclerosis (MS). We aimed to investigate whether the incidence of epilepsy in MS has been affected by the introduction of disease-modifying treatments (DMT) for MS. Materials and methods This retrospective study included 14,557 patients from the Swedish MS register with MS onset between 1991 and 2018. Incident diagnoses of epilepsy or any seizure were identified through cross-linkage with the National Patient Register. Next, yearly prevalence of epilepsy as well as 5- and 10 years incidence of epilepsy or any seizure for consecutive years of MS onset were estimated, the latter with Kaplan-Meier analysis. Cox regression was used to adjust the association between the year of MS onset and incidence of epilepsy for baseline variables. Results Prevalence of epilepsy in the MS cohort increased from 0.34% in 1991 to 2.54% in 2018 (yearly odds: 1.26 [1.22, 1.29]). The 5 years incidence rate of epilepsy, ranging from 0.4% (95% CI 0.008-0.79%) to 1.3% (95% CI 0.71-1.89%), and the 10 years incidence rate of epilepsy, ranging from 1.1% (95% CI 0.31-1.88%) to 2.6% (95% CI 1.22-3.97%) showed no significant trends (p = .147 and p = .418, respectively). Similarly, no significant trends were found for the incidences of any seizure. The incidence trends of epilepsy remained not significant after adjusting for sex, MS onset type (relapsing or progressive onset), or age at MS onset. Conclusions Our findings do not support the hypothesis that the introduction of novel DMT for MS has reduced the incidence of epilepsy among MS patients.Keywords
Funding Information
- Svenska Läkaresällskapet
- Svenska Sällskapet för Medicinsk Forskning
This publication has 33 references indexed in Scilit:
- Immunomodulatory therapies delay disease progression in multiple sclerosisMultiple Sclerosis Journal, 2016
- The Swedish MS registry – clinical support tool and scientific resourceActa Neurologica Scandinavica, 2015
- Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension StudyMultiple Sclerosis International, 2015
- Multiple sclerosis and seizures: incidence and prevalence over 40 yearsActa Neurologica Scandinavica, 2014
- Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugsMultiple Sclerosis Journal, 2012
- Geographical Variations in Sex Ratio Trends over Time in Multiple SclerosisPLOS ONE, 2012
- Clinical correlates of grey matter pathology in multiple sclerosisBMC Neurology, 2012
- Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal studyJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Multiple sclerosis and epileptic seizuresMultiple Sclerosis Journal, 2010
- Extensive cortical inflammation is associated with epilepsy in multiple sclerosisZeitschrift für Neurologie, 2008